These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33811730)

  • 21. Clinical outcomes of complex real-world diabetic patients treated with amphilimus sirolimus-eluting stents or zotarolimus-eluting stents: A single-center registry.
    Rozemeijer R; Benedetto D; Kraaijeveld AO; Voskuil M; Stein M; Timmers L; Rittersma SZ; Agostoni P; Doevendans PA; Stella PR
    Cardiovasc Revasc Med; 2018 Jul; 19(5 Pt A):521-525. PubMed ID: 29137966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry.
    Sardella G; Stella P; Chiarito M; Leone AM; Balian V; Prosperi F; Sorropago G; Mancone M; Calcagno S; Briguori C; Stefanini GG
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):884-891. PubMed ID: 28707375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
    Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
    Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
    Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
    JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential long-term outcomes of zotarolimus-eluting stents compared with sirolimus-eluting and paclitaxel-eluting stents in diabetic and nondiabetic patients: two-year subgroup analysis of the ZEST randomized trial.
    Jang SJ; Park DW; Kim WJ; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2013 Jun; 81(7):1106-14. PubMed ID: 22899589
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Coronary Calcification on Clinical Outcomes After Implantation of Newer-Generation Drug-Eluting Stents.
    Hemetsberger R; Abdelghani M; Toelg R; Mankerious N; Allali A; Garcia-Garcia HM; Windecker S; Lefèvre T; Saito S; Slagboom T; Kandzari D; Koolen J; Waksman R; Richardt G
    J Am Heart Assoc; 2021 Jun; 10(12):e019815. PubMed ID: 34056911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
    JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes Among Diabetic Patients Undergoing Percutaneous Coronary Intervention With Contemporary Drug-Eluting Stents: Analysis From the BIONICS Randomized Trial.
    Konigstein M; Ben-Yehuda O; Smits PC; Love MP; Banai S; Perlman GY; Golomb M; Ozan MO; Liu M; Leon MB; Stone GW; Kandzari DE
    JACC Cardiovasc Interv; 2018 Dec; 11(24):2467-2476. PubMed ID: 30573057
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nobori-Biolimus-Eluting Stents versus Resolute Zotarolimus-Eluting Stents in Patients Undergoing Coronary Intervention: A Propensity Score Matching.
    Tantawy A; Ahn CM; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Yonsei Med J; 2017 Mar; 58(2):290-295. PubMed ID: 28120558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year clinical outcome of biodegradable polymer sirolimus-eluting stent in diabetic patients: Insight from the ULISSE registry (ULtimaster Italian multicenter all comerS Stent rEgistry).
    Beneduce A; Ferrante G; Ielasi A; Pivato CA; Chiarito M; Cappelletti A; Baldetti L; Magni V; Prati E; Falcone S; Pierri A; De Martini S; Montorfano M; Parisi R; Rutigliano D; Locuratolo N; Anzuini A; Tespili M; Margonato A; Benassi A; Briguori C; Reimers B; Fabbiocchi F; Bartorelli A; Colombo A; Godino C
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):255-265. PubMed ID: 31905259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
    Kereiakes DJ; Windecker S; Jobe RL; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Underwood P; Allocco DJ; Meredith IT
    Circ Cardiovasc Interv; 2019 Sep; 12(9):e008152. PubMed ID: 31451014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus.
    Lenz T; Koch T; Joner M; Xhepa E; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Fusaro M; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
    J Am Heart Assoc; 2021 Jun; 10(12):e020165. PubMed ID: 34075784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.